Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2022 04:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase...
January 19, 2022 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in...
January 18, 2022 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the...
January 12, 2022 06:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation...
January 09, 2022 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological...
December 19, 2021 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Included in FTSE Russell Indexes

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 19, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by...
December 14, 2021 00:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing...
December 10, 2021 05:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the...
December 05, 2021 19:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO...
December 03, 2021 00:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, following the 2021...